Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to standardise the use of Pathological Demand Avoidance for autism diagnosis.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Pathological Demand Avoidance (PDA) is most often understood as a characteristic of, or observed in, some autistic people, but professional consensus on its status is still required. PDA is not a recognised and stand-alone diagnosis within the Diagnostic and Statistical Manual of Mental Disorders or the International Classification of Disease.
It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including assessment services for autistic people, in line with National Institute for Health and Care Excellence (NICE) guidelines.
The NICE guideline, Autism spectrum disorder in under 19s: recognition, referral and diagnosis, recommends that as part of autism assessments, healthcare workers should consider PDA, and carry out appropriate referrals.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has for the future of Long Covid clinics.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
Commissioning of post-COVID-19 services is the responsibility of local integrated care boards.
At a national level, NHS England is currently undertaking a stocktake, commissioned in September 2024 and due to complete at the end of this month, that will provide a more accurate, in-depth overview of the position of post-COVID-19 services throughout England.
The stocktake will inform NHS England’s strategic recommendations, with clear responsibilities and accountability across the organisation, supporting matrix working to ensure these challenges are met with improvements.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to regulate the advertising of vapes in local vape shops on high streets so that they do not appeal to children.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
We know that vapes and other nicotine products are being deliberately branded and advertised to appeal to children. This must be stopped to protect future generations from being hooked on nicotine. The Tobacco and Vapes Bill has been introduced to Parliament, and bans vapes and nicotine products from being deliberately promoted and advertised to children to stop the next generation from becoming hooked on nicotine. The bill will ban all forms of advertising of vaping and other nicotine products, including in local vape shops, as well as sponsorship agreements which promote them.
We must also reduce the visibility and accessibility of vapes to protect children and non-smokers from getting hooked on nicotine. The Tobacco and Vapes Bill will provide powers to introduce future regulations on where and how vapes and other nicotine products can be displayed, including in the windows and inside local vape shops.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he plans to take to implement the fresh approach to supporting unpaid carers recommended by the Darzi Review.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is committed to ensuring that families have the support that they need. We want to ensure that people who care for family and friends are better able to look after their own health and wellbeing.
We have already taken action to support unpaid carers. From April 2025 we will increase the Carer's Allowance weekly earnings limit from £151 a week to £196, the equivalent of 16 hours at the National Living Wage. This means carers can earn up to £10,000 a year whilst still retaining Carer's Allowance, which is approximately an additional £2,000 a year.
Lord Darzi’s independent review of the National Health Service is clear that a fresh approach to supporting and involving unpaid carers is required to improve outcomes for carers, people needing care, and the NHS.
We are carefully considering these findings as part of our 10-year plan for reforming and modernising the NHS, and as we develop plans to reform adult social care, including through the National Care Service.
All unpaid carers can have their say on the future of the NHS to ensure their voice is heard by sharing their views at the following link:
https://change.nhs.uk/en-GB/projects/start-here
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of local medical committees advising GPs to withdraw from ADHD shared care agreements; and what steps his Department plans to take to ensure there is uninterrupted access to essential medications and care for patients with ADHD.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Shared care arrangements between a specialist service and the patient’s general practice (GP) cover a number of clinical areas. Guidance is in place to help GPs decide whether to accept shared care responsibilities, with further information available at the following link:
National Health Service clinicians need to be content that any prescriptions, or referrals for treatment, are clinically appropriate. If a shared care arrangement cannot be put in place after the treatment has been initiated, the responsibility for continued prescribing remains with the specialist clinician, and this applies to both NHS and private medical care. However, a GP who had previously agreed to, and had been deploying, a shared care agreement would need to demonstrate clear reasoning as to why they can no longer support this, and they have a responsibility, along with the specialist clinician, to secure continuity of care for their patient.
Where possible, we encourage patients to raise any concerns directly with their GP in the first instance, as this is usually the fastest method of resolution, and can help to build a practice patient relationship.
The Department has been working hard with industry and NHS England to help resolve the supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.
We are continuing to work to resolve the supply issues, where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. To improve supply and resiliency, we are also working with prospective new suppliers of methylphenidate prolonged-release tablets to expand the UK supplier base.
In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the rise in employer National Insurance Contributions on (a) local carer support organisations and (b) their ability to provide support to unpaid carers in their area.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
To enable local authorities to support key services such as adult social care, the Government will make up to £3.7 billion of additional funding available for social care authorities in 2025/26, which includes an £880 million increase in the Social Care Grant.
The Government is also committed to ensuring that families have the support that they need. To support unpaid carers, from April 2025 the Government will increase the Carer's Allowance weekly earnings limit from £151 a week to £196. This means carers can earn up to £10,000 a year whilst still retaining Carer's Allowance, which is approximately an additional £2,000 a year.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the provision of care for people with ME.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made on the adequacy of the implementation of National Institute for Health and Care Excellence (NICE) guidance NG206 on myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). NICE guidelines are not mandatory, but the Government does expect healthcare commissioners to take the guidelines fully into account in designing services to meet the needs of their local population, and to work towards their implementation over time.
There are steps that the Government is taking to improve care for patients with ME/CFS. It is a priority for the Department to publish the final ME/CFS delivery plan. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish it at the end of March 2025.
The Department is also currently working with NHS England to develop an e-learning course on ME/CFS for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes.
Additionally, the Government funds research into ME/CFS through the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC), through UK Research and Innovation. In 2020, the NIHR and the MRC came together to fund the world’s largest genome-wide association study of ME/CFS. This £3.2 million study, termed DecodeME, will analyse samples from 25,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. Further details of the study are available at the following link:
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of implementation of NICE guideline NG206 on myalgic encephalomyelitis.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made on the adequacy of the implementation of National Institute for Health and Care Excellence (NICE) guidance NG206 on myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). NICE guidelines are not mandatory, but the Government does expect healthcare commissioners to take the guidelines fully into account in designing services to meet the needs of their local population, and to work towards their implementation over time.
There are steps that the Government is taking to improve care for patients with ME/CFS. It is a priority for the Department to publish the final ME/CFS delivery plan. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish it at the end of March 2025.
The Department is also currently working with NHS England to develop an e-learning course on ME/CFS for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes.
Additionally, the Government funds research into ME/CFS through the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC), through UK Research and Innovation. In 2020, the NIHR and the MRC came together to fund the world’s largest genome-wide association study of ME/CFS. This £3.2 million study, termed DecodeME, will analyse samples from 25,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. Further details of the study are available at the following link:
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Dynamic Support Register in preventing autistic people from being detained in mental health hospitals.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
NHS England published updated policy and guidance on Dynamic Support Registers (DSRs) and Care (Education) and Treatment Reviews (C(E)TRs) on 25 January 2023, for implementation from 1 May 2023. The purpose of the updated policy and guidance is to help ensure that people with a learning disability and autistic people get the right support in their communities, and to prevent hospital admission.
NHS England produced the updated policy and guidance following a process of reviewing the learning since the inception of DSRs and C(E)TRs, including consultation and engagement with people with lived experience. This process included drawing on the findings of the Norfolk Safeguarding Adults Board’s review of the deaths of Joanna, Jon, and Ben at Cawston Park in Norfolk and the subsequent safe and wellbeing reviews for all people with a learning disability and autistic people in mental health hospitals, to ensure they are an effective provision.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to support Integrated Care Boards to ensure appropriate provision of autism (a) assessment and (b) support services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department is currently considering next steps to improve diagnostic assessment and support for autistic people. It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including autism assessment and support services, in line with National Institute for Health and Care Excellence guidelines.
On 5 April 2023, NHS England published a national framework and operational guidance to deliver improved outcomes in all-age autism assessment pathways. This guidance will help ICBs and the National Health Service to deliver improved outcomes for children, young people, and adults referred to an autism assessment service. The guidance also sets out what support should be available before an assessment, and what support should follow a recent diagnosis of autism based on the available evidence. In 2024/25, £4.3 million is available nationally to improve services for autistic children and young people, including autism assessment services.